Keith Stewart, MD from Mayo Clinic Division of Hematology and Oncology discusses the first phase 3 trial of a new drug added to a standard and the must use triplet therapy early in the diseases course at the 2017 American Society of Hematology.
The First Phase 3 Trial of a New Drug Added to a Standard – Must use Triplet Therapy early in the diseases course
